Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

AH. Wei, P. Montesinos, V. Ivanov, CD. DiNardo, J. Novak, K. Laribi, I. Kim, DA. Stevens, W. Fiedler, M. Pagoni, O. Samoilova, Y. Hu, A. Anagnostopoulos, J. Bergeron, JZ. Hou, V. Murthy, T. Yamauchi, A. McDonald, B. Chyla, S. Gopalakrishnan, Q....

. 2020 ; 135 (24) : 2137-2145. [pub] 20200611

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21012476

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in this international phase 3 randomized double-blind placebo-controlled trial. Patients (N = 211) were randomized 2:1 to venetoclax (n = 143) or placebo (n = 68) in 28-day cycles, plus low-dose cytarabine (LDAC) on days 1 to 10. Primary end point was overall survival (OS); secondary end points included response rate, transfusion independence, and event-free survival. Median age was 76 years (range, 36-93 years), 38% had secondary AML, and 20% had received prior hypomethylating agent treatment. Planned primary analysis showed a 25% reduction in risk of death with venetoclax plus LDAC vs LDAC alone (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.52-1.07; P = .11), although not statistically significant; median OS was 7.2 vs 4.1 months, respectively. Unplanned analysis with additional 6-month follow-up demonstrated median OS of 8.4 months for the venetoclax arm (HR, 0.70; 95% CI, 0.50-0.98; P = .04). Complete remission (CR) plus CR with incomplete blood count recovery rates were 48% and 13% for venetoclax plus LDAC and LDAC alone, respectively. Key grade ≥3 adverse events (venetoclax vs LDAC alone) were febrile neutropenia (32% vs 29%), neutropenia (47% vs 16%), and thrombocytopenia (45% vs 37%). Venetoclax plus LDAC demonstrates clinically meaningful improvement in remission rate and OS vs LDAC alone, with a manageable safety profile. Results confirm venetoclax plus LDAC as an important frontline treatment for AML patients unfit for intensive chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03069352.

3rd Faculty of Medicine Charles University Prague Czech Republic

AbbVie Inc North Chicago IL

Almazov National Medical Research Center Saint Petersburg Russia

Centre Hospitalier Le Mans Le Mans France

Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est de l'Île de Montréal Installation Maisonneuve Rosemont Montreal QC Canada

Centro de Investigación Biomedica en Red en Cancer Instituto Carlos 3 Madrid Spain

Department of Internal Medicine and Hematology University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX

Evaggelismos General Hospital Athens Greece

George Papanicolaou General Hospital Thessaloniki Greece

Heartlands Hospital Birmingham United Kingdom

Hospital Universitario y Politecnico La Fe Valencia Spain

Hubertus Wald University Cancer Center University Medical Center Hamburg Eppendorf Hamburg Germany

Laiko General Hospital National and Kapodistrian University of Athens Medical School Athens Greece

Leukaemia Translational Research Central Clinical School Monash University Melbourne VIC Australia

Netcare Pretoria East Hospital Pretoria South Africa

Nizhny Novgorod Regional Clinical Hospital Nizhny Novgorod Russia

Norton Cancer Institute Louisville KY

Seoul National University Hospital Seoul South Korea

The Alfred Hospital Melbourne VIC Australia

Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

University of Fukui Hospital Fukui Japan

University of Pittsburgh Medical Center Cancer Center Pittsburgh PA

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012476
003      
CZ-PrNML
005      
20240516081828.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2020004856 $2 doi
035    __
$a (PubMed)32219442
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wei, Andrew H $u The Alfred Hospital, Melbourne, VIC, Australia ; Leukaemia Translational Research, Central Clinical School, Monash University, Melbourne, VIC, Australia
245    10
$a Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial / $c AH. Wei, P. Montesinos, V. Ivanov, CD. DiNardo, J. Novak, K. Laribi, I. Kim, DA. Stevens, W. Fiedler, M. Pagoni, O. Samoilova, Y. Hu, A. Anagnostopoulos, J. Bergeron, JZ. Hou, V. Murthy, T. Yamauchi, A. McDonald, B. Chyla, S. Gopalakrishnan, Q. Jiang, W. Mendes, J. Hayslip, P. Panayiotidis
520    9_
$a Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Adults age ≥18 years with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in this international phase 3 randomized double-blind placebo-controlled trial. Patients (N = 211) were randomized 2:1 to venetoclax (n = 143) or placebo (n = 68) in 28-day cycles, plus low-dose cytarabine (LDAC) on days 1 to 10. Primary end point was overall survival (OS); secondary end points included response rate, transfusion independence, and event-free survival. Median age was 76 years (range, 36-93 years), 38% had secondary AML, and 20% had received prior hypomethylating agent treatment. Planned primary analysis showed a 25% reduction in risk of death with venetoclax plus LDAC vs LDAC alone (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.52-1.07; P = .11), although not statistically significant; median OS was 7.2 vs 4.1 months, respectively. Unplanned analysis with additional 6-month follow-up demonstrated median OS of 8.4 months for the venetoclax arm (HR, 0.70; 95% CI, 0.50-0.98; P = .04). Complete remission (CR) plus CR with incomplete blood count recovery rates were 48% and 13% for venetoclax plus LDAC and LDAC alone, respectively. Key grade ≥3 adverse events (venetoclax vs LDAC alone) were febrile neutropenia (32% vs 29%), neutropenia (47% vs 16%), and thrombocytopenia (45% vs 37%). Venetoclax plus LDAC demonstrates clinically meaningful improvement in remission rate and OS vs LDAC alone, with a manageable safety profile. Results confirm venetoclax plus LDAC as an important frontline treatment for AML patients unfit for intensive chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03069352.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a bicyklické sloučeniny heterocyklické $x aplikace a dávkování $7 D019086
650    _2
$a cytarabin $x aplikace a dávkování $7 D003561
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a akutní myeloidní leukemie $x farmakoterapie $x genetika $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a indukce remise $7 D012074
650    _2
$a sulfonamidy $x aplikace a dávkování $7 D013449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Montesinos, Pau $u Hospital Universitario y Politecnico La Fe, Valencia, Spain ; Centro de Investigación Biomedica en Red en Cancer (CIBERONIC), Instituto Carlos III, Madrid, Spain
700    1_
$a Ivanov, Vladimir $u Almazov National Medical Research Center, Saint Petersburg, Russia
700    1_
$a DiNardo, Courtney D $u Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
700    1_
$a Novak, Jan $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic ; Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Laribi, Kamel $u Centre Hospitalier Le Mans, Le Mans, France
700    1_
$a Kim, Inho $u Seoul National University Hospital, Seoul, South Korea
700    1_
$a Stevens, Don A $u Norton Cancer Institute, Louisville, KY
700    1_
$a Fiedler, Walter $u Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Pagoni, Maria $u Evaggelismos General Hospital, Athens Greece
700    1_
$a Samoilova, Olga $u Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia
700    1_
$a Hu, Yu $u Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
700    1_
$a Anagnostopoulos, Achilles $u George Papanicolaou General Hospital, Thessaloniki, Greece
700    1_
$a Bergeron, Julie $u Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est-de-l'Île-de-Montréal (CIUSSSEMTL), Installation Maisonneuve-Rosemont, Montreal, QC, Canada $7 xx0317379
700    1_
$a Hou, Jing-Zhou $u University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA
700    1_
$a Murthy, Vidhya $u Heartlands Hospital, Birmingham, United Kingdom
700    1_
$a Yamauchi, Takahiro $u University of Fukui Hospital, Fukui, Japan
700    1_
$a McDonald, Andrew $u Netcare Pretoria East Hospital, Pretoria, South Africa
700    1_
$a Chyla, Brenda $u AbbVie, Inc., North Chicago, IL; and
700    1_
$a Gopalakrishnan, Sathej $u AbbVie, Inc., North Chicago, IL; and
700    1_
$a Jiang, Qi $u AbbVie, Inc., North Chicago, IL; and
700    1_
$a Mendes, Wellington $u AbbVie, Inc., North Chicago, IL; and
700    1_
$a Hayslip, John $u AbbVie, Inc., North Chicago, IL; and
700    1_
$a Panayiotidis, Panayiotis $u Laiko General Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 135, č. 24 (2020), s. 2137-2145
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32219442 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20240516081823 $b ABA008
999    __
$a ok $b bmc $g 1650773 $s 1132855
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 135 $c 24 $d 2137-2145 $e 20200611 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options